Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
esomeprazole + amoxicillin + clarithromycin + levofloxacin
- Development stage
- Unknown
- Lead developer
- Assistance publique - Hôpitaux de Paris
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Esomeprazole + amoxicillin + clarithromycin + levofloxacin is a tailored, PCR-guided triple therapy regimen used for the eradication of *Helicobacter pylori* infection [MP028]. In this regimen, patients receive esomeprazole and amoxicillin combined with either clarithromycin (for clarithromycin-susceptible strains) or levofloxacin (for clarithromycin-resistant strains) [MP028]. This personalized approach aims to optimize eradication rates and minimize unnecessary antibiotic exposure in regions with high rates of clarithromycin resistance [MP028].
- Other names
- EAC/L14tailored EAC/L14tailored PCR-guided triple therapy
02
Targets
23S rRNA (23S ribosomal RNA)GyrA (DNA gyrase subunit A)GyrB (DNA gyrase subunit B)Topo IV (Bacterial Topoisomerase IV)ParE (DNA topoisomerase IV subunit B)PBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)PBP2 (Penicillin-binding protein 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on esomeprazole + amoxicillin + clarithromycin + levofloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on esomeprazole + amoxicillin + clarithromycin + levofloxacin.